| Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates GG Zom, S Khan, CM Britten, V Sommandas, MGM Camps, NM Loof, ... Cancer immunology research 2 (8), 756-764, 2014 | 122 | 2014 |
| TLR ligand–peptide conjugate vaccines: toward clinical application GGP Zom, S Khan, DV Filippov, F Ossendorp Advances in immunology 114, 177-201, 2012 | 107 | 2012 |
| Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication GG Zom, MM Willems, S Khan, TC van der Sluis, JW Kleinovink, ... Journal for immunotherapy of cancer 6, 1-13, 2018 | 75 | 2018 |
| TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients GG Zom, MJP Welters, NM Loof, R Goedemans, S Lougheed, ... Oncotarget 7 (41), 67087, 2016 | 63 | 2016 |
| Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer LA Koopman, MG Terp, GG Zom, ML Janmaat, K Jacobsen, ... JCI insight 4 (21), 2019 | 48 | 2019 |
| N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-like Receptor 2 MM Willems, GG Zom, S Khan, N Meeuwenoord, CJM Melief, ... Journal of medicinal chemistry 57 (15), 6873-6878, 2014 | 48 | 2014 |
| Dual synthetic peptide conjugate vaccine simultaneously triggers TLR2 and NOD2 and activates human dendritic cells GG Zom, MM Willems, NJ Meeuwenoord, NRM Reintjens, E Tondini, ... Bioconjugate Chemistry 30 (4), 1150-1161, 2019 | 35 | 2019 |
| Lipophilic muramyl dipeptide–antigen conjugates as immunostimulating agents MM Willems, GG Zom, N Meeuwenoord, S Khan, F Ossendorp, ... ChemMedChem 11 (2), 190-198, 2016 | 33 | 2016 |
| Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule GG Zom, DV Filippov, GA van der Marel, HS Overkleeft, CJ Melief, ... Oncoimmunology 3 (7), e947892, 2014 | 24 | 2014 |
| HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo Y Dou, N van Montfoort, A van den Bosch, RA de Man, GG Zom, ... The Journal of infectious diseases 217 (5), 827-839, 2018 | 22 | 2018 |
| Design, automated synthesis and immunological evaluation of NOD2-ligand–antigen conjugates MM Willems, GG Zom, N Meeuwenoord, FA Ossendorp, HS Overkleeft, ... Beilstein Journal of Organic Chemistry 10 (1), 1445-1453, 2014 | 16 | 2014 |
| Logic-gated antibody pairs that selectively act on cells co-expressing two antigens SC Oostindie, DA Rinaldi, GG Zom, MJ Wester, D Paulet, K Al-Tamimi, ... Nature Biotechnology 40 (10), 1509-1519, 2022 | 14 | 2022 |
| Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with … FM Speetjens, MJP Welters, M Slingerland, MIE van Poelgeest, ... Journal for ImmunoTherapy of Cancer 10 (10), 2022 | 14 | 2022 |
| Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients Y Dou, DTSL Jansen, A van Den Bosch, RA de Man, N van Montfoort, ... Antiviral Research 178, 104746, 2020 | 14 | 2020 |
| Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol. Res. 2014; 2: 756–764. doi: 10.1158/2326-6066 GG Zom, S Khan, CM Britten, V Sommandas, MG Camps, NM Loof, ... CIR-13-0223.[Abstract][CrossRef][Google Scholar], 0 | 11 | |
| Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res. 2014; 2 (8): 756–764. doi: 10.1158/2326-6066 GG Zom, S Khan, CM Britten, V Sommandas, MG Camps, NM Loof, ... CIR-13-0223.[Abstract][CrossRef][Google Scholar], 0 | 10 | |
| Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res 2 (8): 756–764. doi: 10.1158/2326-6066 GG Zom, S Khan, CM Britten, V Sommandas, MG Camps, NM Loof, ... CIR-13-0223, 2014 | 5 | 2014 |
| T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors J Middelburg, M Sluijter, G Schaap, B Göynük, K Lloyd, V Ovcinnikovs, ... Nature Communications 15 (1), 48, 2024 | 4 | 2024 |
| Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides. FM Speetjens, MJP Welters, M Slingerland, P de Vos van Steenwijk, ... Journal of Clinical Oncology 39 (15_suppl), 2614-2614, 2021 | 3 | 2021 |
| Tumor-nonspecific vaccines improve the efficacy of CD3 bispecific antibody therapy in solid tumors J Middelburg, M Sluijter, G Schaap, B Göynük, K Lloyd, V Ovcinnikovs, ... | | 2023 |
